Results 151 to 160 of about 2,157,299 (268)

Protocol for human evaluation of generative artificial intelligence chatbots in clinical consultations. [PDF]

PLoS One
Chiu EK, Chung TW.
europepmc   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

First-in-human evaluation of a no-alpha interleukin-2 mutein: safety and preliminary pharmacodynamic and clinical effect. [PDF]

Front Immunol
Caballero Aguirrechu I, Mestre Fernández B, Soriano García JL, Lim Alonso N, Soto García A, Fleites Calvo V, Mariño de la Puente D, Vega Carvajal G, Ávila Pérez JC, Mendoza Hernández I, García López E, Tarinas Reyes A, García-Pérez G, Díaz Borges C, Ledón Naranjo N, Lozada Chang SL, García Vega Y, Alvárez Lobaina A, Alvárez Cardona M, Lorenzo-Luaces Alvárez P, Crombet Ramos T, Carmenate Portilla T, León Monzón K.   +22 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Is AI the future of evaluation in medical education?? AI vs. human evaluation in objective structured clinical examination. [PDF]

BMC Med Educ
Tekin M, Yurdal MO, Toraman Ç, Korkmaz G, Uysal İ.   +4 more
europepmc   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

A high-affinity CEA-targeted nanobody for ⁶⁸Ga PET imaging and ¹⁷⁷Lu-based radioisotope therapy: preclinical and first-in-human evaluation. [PDF]

J Nanobiotechnology
Zhang L, Zhou M, Lu C, Zhao P, Shi N, Zhou Y, Yao C, Yang X, Tian J, Wang J, Ma Y, Huang Q, Xu C, Gao P, Zhou W, Hu S, Luo L.   +16 more
europepmc   +1 more source

First-in-human evaluation of [¹¹C]PS13, a novel PET radioligand, to quantify cyclooxygenase-1 in the brain. [PDF]

Eur J Nucl Med Mol Imaging, 2020
Kim MJ, Lee JH, Juarez Anaya F, Hong J, Miller W, Telu S, Singh P, Cortes MY, Henry K, Tye GL, Frankland MP, Montero Santamaria JA, Liow JS, Zoghbi SS, Fujita M, Pike VW, Innis RB.   +16 more
europepmc   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease. [PDF]

Alzheimers Res Ther
Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, Rychkova A, Rhinn H, Tassi I, Ward M, Yeh F, Schwabe T, Paul R, Kenkare-Mitra S, Rosenthal A.   +14 more
europepmc   +1 more source